Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock Sells 10,885 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the sale, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at $1,478,093.33. This represents a 2.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Voyager Therapeutics Price Performance

NASDAQ:VYGR traded up $0.26 during trading hours on Wednesday, hitting $3.11. The company's stock had a trading volume of 706,718 shares, compared to its average volume of 462,863. Voyager Therapeutics, Inc. has a twelve month low of $2.75 and a twelve month high of $9.55. The stock has a fifty day simple moving average of $4.04 and a 200-day simple moving average of $5.43. The company has a market capitalization of $171.69 million, a P/E ratio of 4.38 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.24). The company had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the previous year, the business posted $1.25 earnings per share. On average, equities analysts predict that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on VYGR. Canaccord Genuity Group dropped their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, March 13th. StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the stock an "overweight" rating in a research report on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Finally, Wedbush reiterated an "outperform" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Voyager Therapeutics currently has a consensus rating of "Buy" and an average target price of $13.97.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VYGR. Geode Capital Management LLC raised its position in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company's stock valued at $6,316,000 after purchasing an additional 6,740 shares during the last quarter. FMR LLC raised its holdings in Voyager Therapeutics by 26.9% in the 3rd quarter. FMR LLC now owns 92,498 shares of the company's stock valued at $541,000 after buying an additional 19,622 shares during the last quarter. Barclays PLC boosted its position in Voyager Therapeutics by 55.8% during the 3rd quarter. Barclays PLC now owns 104,462 shares of the company's stock worth $612,000 after buying an additional 37,398 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock worth $223,000 after acquiring an additional 7,573 shares during the last quarter. Finally, Rhumbline Advisers increased its position in Voyager Therapeutics by 3.4% in the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock valued at $405,000 after acquiring an additional 2,354 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.